ALFA Finder| Management target | Revenue FY27 |
|---|
| Revenue growth | Volume-led growth; COVID contributed 25% of recent revenue. |
|---|---|
| Margins | Healthy 29-30% margins driven by fixed doctor salaries and high occupancy. |
| Demand visibility | Strong domestic demand; international patient share remains low at <1%. |
| Management confidence | Balanced and conservative regarding long-term margin sustainability during expansion. |
Growth
Revenue growth is volume-led with 25% contribution from high-margin COVID-related cases and insurance/cash mix.
Outlook
Management targets 1.25x revenue on ₹100 crore capex with 20-25% EBITDA within 3-5 years post-maturation.
Risks
Margins face dilution risk as heavy capex in Chennai and Bangalore comes online in 2-3 years.
Last quarter's promises, checked
Delivered
- Guided Thane EBITDA break-even by March → Delivered Neutral (= BEAT)
- Guided 10,000 brain tumor surgeries milestone → Delivered 10,000+ (= BEAT)
- Guided Kondapur expansion to 800 beds → Delivered Phase 1 commissioning June (= BEAT)
Partly delivered
- Guided debt peaking out → Delivered ₹3,000cr+ with QIP needed to retire ₹1,000cr (= PARTIAL)
- Guided insurance empanelment → Delivered 70% in Thane but Bangalore delayed 3-4 months (= PARTIAL)
Missed
- Guided PAT ₹106cr (Q4FY25) → Delivered ₹33cr (= MISS)
- Guided EPS growth → Delivered -37.2% YoY (= MISS)
- Guided EBITDA margin 25.3% (Q4FY25) → Delivered 19.9% (= MISS)
Earnings Call Transcript filed with BSE, NSE: KIMS. Summary written with AI assistance from the document.
Krishna Institute of Medical Sciences Ltd: key numbers
- Share price
- ₹722.00
- Market cap
- ₹30,324 Cr
- Revenue (annual)
- ₹3,905 Cr
- Net profit (annual)
- ₹241.4 Cr
- P/E (TTM)
- 142.8×Sector 54.5×
- Promoter holding
- 32.66%+0.16% QoQ
- FII holding
- 15.01%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Krishna Institute of Medical Sciences Ltd
All →Krishna Institute of Medical Sciences Earnings Call Transcript: Key Takeaways
KIMS delivered strong revenue growth led by Kondapur's rapid ramp-up, despite temporary margin compression from new oncology programs.
Krishna Institute of Medical Sciences Other Announcement
KIMS's CARE Ratings monitoring report shows ₹1,311.81 crore of the ₹1,476.45 crore QIP proceeds utilised till Q2 FY27. No deviation from the stated objects was reported.
Krishna Institute of Medical Sciences Management Change
KIMS re-appointed Dr. Abhinay Bollineni as Director & CEO, Dr. Bhaskara Rao Bollineni as CMD, and Ms. Dandamudi Anitha as Whole-time Director. Terms start in 2027.
- Execution
- 5 years
Krishna Institute of Medical Sciences Investor Presentation: Key Takeaways
Q2 FY27 total revenue Rs13,630 Mn (+41.3% YoY), EBITDA Rs2,789 Mn (20.5% margin), PAT Rs757 Mn (+5.1% YoY). Expansion via 700+ beds planned.
Krishna Institute of Medical Sciences Results Update
KIMS reported Q2 FY27 consolidated revenue of Rs 1,363 Crore, up 41.3% YoY, with PAT of Rs 76 Crore. EBITDA rose 34% YoY to Rs 279 Crore.
Krishna Institute of Medical Sciences Q2 FY27 Results: Net Profit ₹74.6 Cr, Up 3.6% YoY
Krishna Institute of Medical Sciences Ltd reported revenue from operations of ₹1,344 Cr (+39.9% YoY) and net profit of ₹74.6 Cr (+3.6% YoY) for Q2 FY27.
- Key figure
- Net profit ₹74.6 Cr · +3.6% YoY